{"id":"flublok-influenza-vaccination","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site soreness"},{"rate":"20-30","effect":"Headache"},{"rate":"15-25","effect":"Muscle aches"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-10","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FluBlok uses recombinant DNA technology to produce hemagglutinin (HA) antigens from influenza virus strains without using eggs or live virus. The recombinant HA proteins are presented to the immune system to generate protective antibody responses against seasonal influenza strains. This approach allows for faster production and avoids potential issues associated with egg-based vaccine manufacturing.","oneSentence":"FluBlok is a recombinant influenza vaccine that stimulates the immune system to produce antibodies against influenza virus surface proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:50.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza illness caused by influenza A and B viruses in adults 18 years of age and older"}]},"trialDetails":[{"nctId":"NCT02872311","phase":"NA","title":"Open-Label Influenza Vaccine Evaluation","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2016-09","conditions":"Immune Response","enrollment":179},{"nctId":"NCT07240922","phase":"PHASE4","title":"The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-10-01","conditions":"Influenza","enrollment":600},{"nctId":"NCT05479370","phase":"PHASE3","title":"Immunogenicity Trial of 3 Influenza Vaccines","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-09-29","conditions":"Influenza Vaccination","enrollment":366},{"nctId":"NCT06518577","phase":"PHASE4","title":"Immunogenicity of Influenza Vaccinations","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-09","conditions":"Influenza","enrollment":605},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT04576377","phase":"PHASE4","title":"Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2020-10-05","conditions":"Influenza, Human","enrollment":977},{"nctId":"NCT03330132","phase":"PHASE4","title":"Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-10-07","conditions":"Influenza, Human","enrollment":1861},{"nctId":"NCT04523324","phase":"PHASE4","title":"Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2019-10-31","conditions":"Influenza","enrollment":577},{"nctId":"NCT04484532","phase":"EARLY_PHASE1","title":"Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2017-10-17","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":130},{"nctId":"NCT03965195","phase":"PHASE4","title":"Recombinant Influenza Vaccination in U.S. Nursing Homes","status":"UNKNOWN","sponsor":"Insight Therapeutics, LLC","startDate":"2019-07-20","conditions":"Influenza, Influenza -Like Illness, Influenza, Human","enrollment":1989},{"nctId":"NCT03969641","phase":"PHASE4","title":"Safety of RIV4 Versus IIV4 in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-09-05","conditions":"Safety, Adverse Event Following Immunisation, Birth Outcomes","enrollment":384},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT00539981","phase":"PHASE3","title":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09-15","conditions":"Influenza","enrollment":4648},{"nctId":"NCT02747407","phase":"","title":"Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-05","conditions":"Astrocytoma, Glioma, Oligodendroglioma","enrollment":55},{"nctId":"NCT02600585","phase":"","title":"Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2015-11","conditions":"Human Influenza","enrollment":254648},{"nctId":"NCT01825200","phase":"PHASE3","title":"Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2013-03","conditions":"Influenza","enrollment":2640},{"nctId":"NCT00539864","phase":"PHASE3","title":"Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2007-09","conditions":"Influenza","enrollment":602},{"nctId":"NCT01195038","phase":"PHASE2","title":"Immunogenicity and Safety Study of a Booster Vaccination With a Recombinant H5N1 Influenza HA Vaccine in Primed Adults","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2010-10","conditions":"Influenza","enrollment":87},{"nctId":"NCT00980447","phase":"PHASE2","title":"Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2009-10","conditions":"Influenza, Virus Diseases","enrollment":90},{"nctId":"NCT00395174","phase":"PHASE3","title":"Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2006-10","conditions":"Influenza","enrollment":870},{"nctId":"NCT00336453","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics","status":"COMPLETED","sponsor":"Protein Sciences Corporation","startDate":"2006-10","conditions":"Influenza","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FluBlok","rHA","rHA0","recombinant hemagglutinin"],"phase":"phase_3","status":"active","brandName":"FluBlok Influenza Vaccination","genericName":"FluBlok Influenza Vaccination","companyName":"Protein Sciences Corporation","companyId":"protein-sciences-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"FluBlok is a recombinant influenza vaccine that stimulates the immune system to produce antibodies against influenza virus surface proteins. Used for Prevention of influenza illness caused by influenza A and B viruses in adults 18 years of age and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}